A Phase II Study of Allogeneic Large Multivalent Immunogen (LMI) Vaccine and IL-2 for the Treatment of Stable Metastatic Breast Cancer

Trial Information

A Phase II Study of Allogeneic Large Multivalent Immunogen (LMI) Vaccine and IL-2 for the Treatment of Stable Metastatic Breast Cancer

OBJECTIVES:

Primary

- To determine the efficacy of allogeneic large multivalent immunogen (LMI) vaccine and
aldesleukin, as defined by clinical benefit rate (percentage of patients demonstrating
a complete response, partial response, or disease stabilization as assessed by RECIST
criteria), in women with stable metastatic breast cancer.

Secondary

- To measure the immune response in patients treated with this regimen.

- To determine the progression-free survival of patients treated with this regimen.

- To determine the 1- and 2-year overall survival rates in patients treated with this
regimen.

- To determine the safety profile and toxicity of this regimen in these patients.

OUTLINE: Patients receive allogeneic large multivalent immunogen (LMI) vaccine intradermally
on day 1 and aldesleukin subcutaneously on days 7 and 8. Treatment repeats every 28 days in
the absence of disease progression or unacceptable toxicity. Patients with disease
progression after 2 courses of vaccine therapy resume the chemotherapy regimen for which
prior disease stabilization was achieved. Beginning 2-4 days after completion of
chemotherapy, patients receive one dose of LMI vaccine followed by aldesleukin on days 7 and
8. Patients achieving at least stable disease continue to receive LMI vaccine and
aldesleukin as above. Treatment repeats every 28 days in the absence of disease progression
or unacceptable toxicity.

- Hepatic: bilirubin ≤ 3 times the upper limit of normal (× ULN) for patients
without tumor involvement of the liver and ≤ 5 X ULN for patients with tumor
involvement of the liver; aspartate transaminase (AST) ≤ 2.5 × ULN for patients
without tumor involvement of the liver and ≤ 5 X ULN for patients with tumor
involvement of the liver

- Meets eligibility criteria for and agrees to enroll in "MT1999-06: Vaccination with
Tetanus Toxoid and Keyhole Limpet Hemocyanin (KLH) to Assess Antigen-Specific Immune
Responses" (IRB # 9904M01581, CPRC #2002LS032). Patients who have had tetanus toxoid
within the last 7 years will not receive the tetanus vaccine component. For patients
who do not know the year of their last tetanus vaccine, tetanus toxoid will be given
per protocol. Subjects allergic to seafood will not be co-enrolled into MT1996-06.

- Women of childbearing potential and their partners are required to use an effective
method of contraception (ie, a hormonal contraceptive, intra-uterine device,
diaphragm with spermicide, condom with spermicide, or abstinence) during the study
and for 3 months after the last dose of study drug.

- Voluntary written informed consent before performance of any study-related procedure
not part of normal medical care, with the understanding that consent may be withdrawn
by the subject at any time without prejudice to future medical care.

Exclusion criteria:

- History of untreated or active brain metastases or positive brain scan at enrollment.
Patients with previously treated brain metastases are eligible if stable by CT or MRI
for at least 3 months.

- Concurrent malignancy other than non-melanoma skin cancer or carcinoma in situ of the
cervix

- Symptomatic pulmonary disease (symptoms of dyspnea or rales, wheezes or rhonchi on
physical exam) will require pulmonary function testing (PFTs). Those with FEV1 <50%
of predicted or corrected DLCO <50% are not eligible.

- Hypersensitivity to any component of the vaccine, including Thimerosal, a mercury
derivative, is a contraindication (taken from tetanus toxoid package insert).

- The occurrence of any type of neurologic symptoms to tetanus vaccine in the past is a
contraindication to further use (taken from tetanus toxoid package insert).

- Pregnant (positive pregnancy test) or lactating women. Use of LMI vaccine during
pregnancy is not approved for use by the FDA during pregnancy. IL-2 is pregnancy
category C - risk in pregnancy cannot be ruled out.

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.